HispanicBusiness

Other income, (net) totaled $428,000 compared to other expense, (net) of $1.2 million for the quarters ended September 30, 2012 and 2011, respectively. The change was primarily due to $689,000 in income compared with a $780,000 loss associated with the non-cash change in fair value of derivative liabilities.

Net loss to common stockholders for the third quarter of 2012 was $3.78 million, or $0.04 per share, compared with a $2.29 million loss, or $0.04 in the same period last year.

Year-to-Date Results

Total revenues for the first nine months of 2012 were $8.46 million, up 97% from $4.29 million in the first nine months of 2011. Total product sales for the first nine months were $5.20 million, up 21% from $4.29 million in the comparable period in 2011. For the nine-month period, overall gross margin increased to 67% from 53%. The increase was primarily due to $3.15 million in license fee revenue which had no associated cost of revenue. Gross margin on product sales decreased to 46% from 53%. Operating expenses in the first nine months of the year were $14.91 million compared with $6.04 million in the comparable period last year.

Net loss attributable to common stockholders for the first nine months of 2012 was $15.98 million or $0.20 per share, compared with $4.67 million or $0.09 in 2011.

Cash and Liquidity

Cash and equivalents at September 30 2012 were $5.83 million, compared with $2.25 million as of December 31, 2011. Cash used in operating activities in the third quarter was just under $3 million. Approximately $1.7 million of the operating cash use related to the legacy Aldagen business.

For additional information please see the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2012, filed with the U.S. Securities and Exchange Commission on November 14, 2012.

Conference Call

Cytomedix management will hold a conference call to discuss these results and answer questions beginning at 8:30 a.m. Eastern time on Thursday, November 15, 2012. Shareholders and other interested parties may participate in the call by dialing 877-556-5921 (domestic) or 617-597-5474 (international) and entering passcode 51983274. The call will also be broadcast live on the Internet at www.streetevents.com, www.fulldisclosure.com and www.cytomedix.com. A replay of the conference call will be available beginning two hours after its completion through November 22, 2012 by dialing 888-286-8010 (domestic) or 617-801-6888 (international) and entering passcode 22359860. The call will also be archived for 90 days at www.streetevents.com, www.fulldisclosure.com and www.cytomedix.com.

About Cytomedix, Inc.
Cytomedix, Inc. is a fully integrated regenerative medicine company commercializing and developing innovative platelet and adult stem cell separation products that enhance the body's natural healing processes. The Company's advanced autologous technologies offer clinicians a new treatment paradigm for wound and tissue repair. The Company's patient-derived PRP systems are marketed by Cytomedix in the U.S. and distributed internationally. Our commercial products include the AutoloGel™ System, cleared by the FDA for wound care and the Angel® Whole Blood Separation System. The Company is developing novel regenerative therapies using our proprietary ALDH Bright Cell ("ALDHbr") technology to isolate a unique, biologically active population of a patient's own stem cells. A Phase 2 trial evaluating the use of ALDHbr for the treatment of ischemic stroke is underway. For additional information please visit www.cytomedix.com.